Low-Dose Naltrexone for Autoimmune Diseases and Fibromyalgia? The Unfinished StoryProHealth.com
by Joseph Mercola, MD*
December 21, 2011
One of the Rare Drugs that Actually Helps Your Body to Heal Itself
It is not often that I advocate the use of prescription drugs, but low-dose naltrexone (LDN) is one of those rare exceptions that may hold the promise of helping millions of people with cancer and autoimmune diseases like rheumatoid arthritis, multiple sclerosis, Parkinson's, fibromyalgia, and Crohn's disease, just to name a few.
As a pharmacologically active opioid antagonist, LDN (used 'off-label' in very small doses) works by blocking opioid receptors, which in turn helps activate your body's immune system.
How LDN Harnesses Your Own Body's Chemistry to Fight Disease
The latest research in Experimental Biology and Medicine just confirmed that LDN does in fact target the opioid growth factor (OGF) / opioid growth factor receptor (OGFr) pathway to inhibit cell proliferation. Previous research by professor Ian S. Zagon of The Pennsylvania State University, who also conducted the Experimental Biology and Medicine study, found that OGF regulates the growth of cancer cells, and all cancer cells use the OGF-OGFr pathway in growth regulation. It is through this mechanism that LDN is thought to exert its profound inhibitory effect on cancer growth.
Further, LDN also works with your body's immune system through its interactions with your body's endorphins.
Though most commonly referenced in relation to your mood, endorphins also play a role in pain relief, immune system regulation, growth of cells and angiogenesis (the growth of blood vessels that feed a tumor).
Typically, LDN is taken at bedtime, which blocks your opioid receptors, as well as the reception of endorphins, for a few hours in the middle of the night. This is believed to up-regulate vital elements of your immune system by increasing your body's production of metenkephalin and endorphins (your natural opioids), hence improving your immune function.
Dermatomyositis (an inflammatory muscle disease)
Chronic fatigue syndrome (ME/CFS)
Irritable bowel syndrome (IBS)
And Fibromyalgia [1,2,3]
"The disorders listed above all share a particular feature: In all of them, the immune system plays a central role. Low blood levels of endorphins are generally present, contributing to the disease-associated immune deficiencies."
In 1985, Dr. Bernard Bihari discovered LDN enhanced patients' response to infection with HIV, the virus that causes AIDS. Years later he found that his patients with cancer and autoimmune disease also benefited from LDN.
Dr. Bihari has reportedly treated more than 450 cancer patients with LDN with promising results, including cancers of the bladder, breast, liver, lung, lymph nodes, colon, and rectum. According to Dr. Bihari, nearly a quarter of his patients had at least a 75% reduction in tumor size, and nearly 60% of his patients demonstrated disease stability. He believes LDN's anti-cancer mechanism is likely due to an increase in the:
• Number and density of opiate receptors on the tumor cell membranes, making them more responsive to the growth-inhibiting effects of the already present levels of endorphins, which in turn induces apoptosis (cell death) in the cancer cells
• Absolute numbers of circulating cytotoxic T cells and Natural Killer cells, as well as killer cell activity
• LDN administered for six hours every two days reduced DNA synthesis and cell replication in tissue culture.
• Exposure to LDN in combination with cancer drugs had enhanced anti-cancer action.
• Mice with established ovarian tumors treated with LDN had repressed tumor progression by reducing DNA synthesis and angiogenesis -- but not altering cell survival, indicating it is non-toxic.
• LDN combined with a chemotherapy drug, cisplatin, alleaviated the toxicity associated with cisplatin.
• LDN treatment upregulated the expression of the opioid growth factor, which is the only opioid peptide that tends to inhibit cell growth of ovarian cancer cells.
"It is difficult for many to believe that one drug can accomplish so many tasks. But LDN does not treat symptoms as most drugs do. It actually works way 'upstream' to modulate the basic mechanisms that result in the disease state."
This means there are no friendly sales reps visiting your doctor talking about the potential benefits of this drug in very low doses, and as a result very few physicians are aware of LDN. So, if your physician is not familiar with LDN, you will need to bring it up to him or her, or, alternatively, seek a health care provider who is already knowledgeable at using LDN as a form of treatment. There are a number of pharmacies and compounding pharmacies in the United States and Canada that are reliable sources of the compound in low-dose form.
CAUTION: Important LDN Points to Consider if You Use It
• Avoid slow-release (SR) or timed-release naltrexone. You want to be sure the LDN you receive is in unaltered form that allows you to receive the full dose quickly. Slow-release formulas may not give you the full therapeutic effects.
• Be aware of inactive fillers. Part of the LDN capsule will contain a "neutral" filler material. However, there is some evidence to suggest that calcium carbonate as a filler could interfere with the absorption of LDN. So to be on the safe side, avoid LDN capsules that contain calcium carbonate fillers.
|Dr. Mercola is the founder of the world's most visited natural health web site, Mercola.com. You can learn the hazardous side effects of OTC Remedies by getting a FREE copy of his latest special report The Dangers of Over the Counter Remedies by going to his Report Page.|
1. Low-Dose Naltrexone Reduces the Symptoms of Fibromyalgia" by Sean Mackey, et al., Apr 22, 2009. See also "Inexpensive drug naltrexone appears to relieve fibromyalgia pain in Stanford pilot study."
2. A second, longer term fibromyalgia trial at Stanford by Mackey et al., was recently completed but is not yet published: See ClinicalTrials.gov listing for "Effects of Low Dose Naltrexone in Fibromyalgia."
3. A clinical trial to characterize the "Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain," employing naltrexone in patients with temporomandibular disorder (TMD), is currently (Dec 2011) recruiting participants at the University of Florida.